concept

SYNAPTIC LOSS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about SYNAPTIC LOSS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

105Connections

2Hypotheses

11Analyses

29Outgoing

50Incoming

0Experiments

14Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	SYNAPTIC LOSS
Key Genes/Proteins	AMYLOID
Related Diseases	AGING, ALZHEIMER'S DISEASE, AXONAL TRANSPORT, COGNITIVE DECLINE
Related Pathways	COMPLEMENT CASCADE, COMPLEMENT PATHWAY

Pathway Diagram

graph TD
    SYNAPTIC_LOSS["SYNAPTIC LOSS"]
    SYNAPTIC_LOSS -->|"contributes to"| Alzheimer_s_Disease["Alzheimer's Disease"]
    SYNAPTIC_LOSS -->|"contributes to"| Neurodegeneration["Neurodegeneration"]
    SYNAPTIC_LOSS -.biomarker for.-> Depression["Depression"]
    C1q_C3_CR3_signaling_pathway["C1q/C3-CR3 signaling pathway"] -->|"causes"| SYNAPTIC_LOSS
    Abnormal_Microglial_Phagocytos["Abnormal Microglial Phagocytosis"] -->|"causes"| SYNAPTIC_LOSS
    TREM2["TREM2"] -.protects against.-> SYNAPTIC_LOSS
    MICROGLIA["MICROGLIA"] -->|"mediates"| SYNAPTIC_LOSS
    Impaired_Mitophagy["Impaired Mitophagy"] -->|"causes"| SYNAPTIC_LOSS
    Microglial_Phagocytosis["Microglial Phagocytosis"] -->|"causes"| SYNAPTIC_LOSS
    Microglia["Microglia"] -->|"causes"| SYNAPTIC_LOSS
    COMPLEMENT_ACTIVATION["COMPLEMENT ACTIVATION"] -->|"contributes to"| SYNAPTIC_LOSS

Outgoing (29)

Target	Relation	Type	Str
Alzheimer's Disease	contributes_to	disease	0.90
Neurodegeneration	contributes_to	process	0.90
Major Depression	contributes_to	disease	0.85
Depression	associated_with	disease	0.85
Depression	biomarker_for	disease	0.80
Cognitive impairment	associated_with	process	0.70
HIPPOCAMPUS	regulates	brain_region	0.70
HIPPOCAMPUS	activates	brain_region	0.70
COGNITIVE DECLINE	treats	phenotype	0.70
neurodegeneration	precedes	disease	0.70
network disruption	causes	mechanism	0.70
cognitive decline	causes	phenotype	0.70
neuronal metabolic failure	causes	mechanism	0.70
NEURODEGENERATION	interacts_with	phenotype	0.65
NEURODEGENERATION	biomarker_for	disease	0.60
CA1	associated_with	brain_region	0.50
AXONAL TRANSPORT	associated_with	phenotype	0.50
CA3	associated_with	brain_region	0.50
MMSE	associated_with	biomarker	0.50
CORTEX	associated_with	brain_region	0.50
MELATONIN	associated_with	drug	0.50
DASATINIB	associated_with	drug	0.50
QUERCETIN	associated_with	drug	0.50
WNT SIGNALING	associated_with	pathway	0.45
DENTATE GYRUS	associated_with	brain_region	0.45
HIPPOCAMPUS	associated_with	brain_region	0.45
HYPOTHALAMUS	associated_with	brain_region	0.45
THALAMUS	associated_with	brain_region	0.45
AMYGDALA	associated_with	brain_region	0.45

Incoming (76)

Source	Relation	Type	Str
dysfunctional microglial phagocytosis	causes	process	0.92
neuroinflammation	causes	mechanism	0.90
Complement-Mediated Microglial Engulfment	causes	process	0.90
Impaired Mitophagy	causes	phenotype	0.90
C1q/C3-CR3 signaling pathway	causes	pathway	0.90
Abnormal Microglial Phagocytosis	causes	process	0.90
C1q blockade	prevents	drug	0.90
Microglial Phagocytosis	causes	process	0.90
MICROGLIA	mediates	entity	0.90
SPP1	contributes_to	gene	0.90
APOE	downregulates	gene	0.90
38278523	correlates with	paper	0.90
Activated Microglia	causes	cell_type	0.88
COMPLEMENT ACTIVATION	contributes_to	entity	0.85
APOE	inhibits	protein	0.85
APOE ε2	inhibits	protein	0.85
Lipopolysaccharide	causes	compound	0.85
ATAD3A	promotes	protein	0.85
Inflammasome Signaling	causes	pathway	0.85
Microglia	causes	cell_type	0.85
SMS1	contributes_to	enzyme	0.82
ASTROCYTE	causes	cell_type	0.80
Complement Activation	contributes_to	process	0.80
BDNF	protects_against	protein	0.80
C3	contributes_to	protein	0.75
VGLUT1	causes	protein	0.70
MAC	activates	protein	0.70
CORTEX	causes	brain_region	0.70
CORTEX	regulates	brain_region	0.70
NEUROINFLAMMATION	causes	phenotype	0.70
OXIDATIVE STRESS	activates	phenotype	0.70
OXIDATIVE STRESS	regulates	phenotype	0.70
COMPLEMENT ACTIVATION	causes	phenotype	0.70
ALZHEIMER'S DISEASE	causes	disease	0.70
AMYLOID	activates	protein	0.70
NEURONS	treats	cell_type	0.70
AGING	activates	phenotype	0.70
complement cascade	causes	pathway	0.70
TDP-43 pathology	causes	process	0.70
complement cascade (C1q, C3)	mediates	pathway	0.70
complement inhibition	prevents	process	0.70
microglia	causes	cell_type	0.70
senolytics	prevents	drug	0.70
C1q	causes	protein	0.70
complement activation	causes	pathway	0.70
Complement C1q	causes	pathway	0.70
Complement C3	causes	pathway	0.70
Complement inhibition	prevents	process	0.70
microglial surveillance dysregulation	causes	process	0.70
NLRP3 INFLAMMASOME	activates	pathway	0.65

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Excessive C1q/C3/CR3 complement cascade activation initiates	0.720	neurodegeneration	Synaptic pruning by microglia in neurode
Astrocyte Reactivity Mediated by LCN2 Promotes Synaptic Loss	0.508	neurodegeneration	Legacy Pre-Pipeline Hypothesis Import

Mentioning Analyses (11)

Scientific analyses that reference this entity

Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other

neurodegeneration | 2026-04-25 | 13 hypotheses Top: 0.867

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

Human connectome alterations in Alzheimer's disease: structural and functional n

connectomics | 2026-04-16 | 13 hypotheses Top: 0.535

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple

neuroinflammation | 2026-04-14 | 2 hypotheses Top: 0.586

Why have numerous phase 3 clinical trials failed despite advances in understandi

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.566

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (14)

Multi-agent debates referencing this entity

Debate: Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activat

closed · Rounds: 4 · Score: 0.34 · 2026-04-27

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

What is the role of microglial synaptic pruning in Alzheimer's disease and other

closed · Rounds: 4 · Score: 0.68 · 2026-04-22

Tau pathology spreads through synaptically connected brain regions in Alzheimer

closed · Rounds: 4 · Score: 0.78 · 2026-04-22

AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-4

closed · Rounds: 4 · Score: 0.73 · 2026-04-21

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

How do metabolomic alterations in glucose metabolism, mitochondrial function, an

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

How does the human brain connectome reorganize in Alzheimer's disease, and what

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

Related Research

Hypotheses and analyses mentioning SYNAPTIC LOSS in their description or question text

No additional research found

SYNAPTIC LOSS

Understanding Entity Pages

Pathway Diagram

Outgoing (29)

Incoming (76)

Targeting Hypotheses (2)

Mentioning Analyses (11)

Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

Human connectome alterations in Alzheimer's disease: structural and functional n

Why is TYROBP deficiency neuroprotective when TYROBP is an adapter for multiple

Why have numerous phase 3 clinical trials failed despite advances in understandi

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

What mechanisms underlie TDP-43's contribution to cognitive impairment severity

Metabolomic signatures of neurodegeneration and energy metabolism dysfunction

Trans-synaptic tau spreading and propagation mechanisms in AD

Synaptic pruning by microglia in neurodegeneration

Senolytic therapy for age-related neurodegeneration

Experiments (0)

Related Papers (0)

Debates (14)

Debate: Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activat

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Does the cancer-cystatin-C-TREM2 pathway protect against tau pathology and other

What is the role of microglial synaptic pruning in Alzheimer's disease and other

Tau pathology spreads through synaptically connected brain regions in Alzheimer

AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-4

Do these mechanistic hypotheses explain layer-specific synaptic vulnerability in

How do metabolomic alterations in glucose metabolism, mitochondrial function, an

What is the current clinical trial landscape for AD therapeutics, and which mech

How does the human brain connectome reorganize in Alzheimer's disease, and what

Related Research